At Rezvani Lab in MD Anderson Cancer Center, scientists train immune cells to fight cancer. Photo via Getty Images

Unique cell therapy developed in Houston doses inaugural patient

cancer-fighting innovation

Replay, a genome-writing company headquartered in San Diego, has announced that its first patient has been dosed with an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for relapsed or refractory multiple myeloma.

What does that have to do with Houston? Last year, Replay incorporated a first-in-class engineered TCR-NK cell therapy product company, Syena, using technology developed by Dr. Katy Rezvani at The University of Texas MD Anderson Cancer Center.

Rezvani, a professor of stem cell transplantation and cellular therapy, is the force behind MD Anderson’s Rezvani Lab, a group of 55 people, all focused on harnessing natural killer cells to combat cancer.

“Everybody thinks that the immune system is fighting viruses and infections, but I feel our immune system is capable of recognizing and killing abnormal cells or cells that are becoming cancerous and they're very powerful. This whole field of immunotherapy really refers to the power of the immune system,” Rezvani tells InnovationMap.

Dr. Katy Rezvani is a professor of stem cell transplantation and cellular therapy and the force behind MD Anderson’s Rezvani Lab, which is focused on harnessing natural killer cells to combat cancer. Photo via mdanderson.org

At Rezvani Lab, scientists train immune cells to fight cancer. While cancer drugs like chemotherapy are still the norm, immunotherapy has gained ground, led by Houston research, including the work of Nobel laureate Jim Allison. The harnessed cells are taught to attack cancerous cells, while ignoring healthy ones, says Rezvani. “We’re turning them into heat-seeking missiles,” she explains.

However, there must be a beacon to signal to those “missiles” that there is something to attack. Much of the field has used chimeric antigen receptors (CARs) to achieve that. But they have limitations.

“CARs can only recognize beacons that sit on the surface of the tumor cells,” Rezvani says. “So basically, it's like the tumor cell has to have a hat on it.”

She says that this usually means that the targets that send off a signal are relatively limited, mostly blood cancers. Using T cell receptors (TCRs) may be able to open up the field to look beyond the “hat.” In other words, TCRs can peer inside cells and see what differentiates a tumor cell from healthy cells. With Replay, Rezvani Lab has developed a first-in-class and first-in-human approach of engineering natural killer cells to express the TCR.

There are six different FDA-approved products that use CAR-T cells, but Rezvani says that her TCR-NK-based technology, though still in its early phases, shows great promise.

“We could use it to target many different types of antigens, many different types of cancers, especially solid tumors," she explains. "These cell therapies have a lot of potential — we call them living drugs… It's not like chemotherapy where you have to keep giving different multiple cycles, these cells are very long lived.”

Rezvani, who started her career in London, says that Houston has been instrumental in the success of her lab.

“There are so many opportunities because we have access to some of the most brilliant minds in research,” Rezvani says. “We have some of the best clinicians in the world. We have patients who come to us who are willing to participate in our clinical trials — really put their trust in us — and are committed and want to participate in these clinical studies.”

The role of funding also plays a part. As Rezvani admitted, bringing a new technology to the market is expensive. The philanthropists who help support trials can’t be forgotten among Houston’s finest.

Whether or not Syena produces the first TCR-NK product on the market, Rezvani is enthusiastic and hopeful for the future of her patients.

“The field of immunotherapy is really expanding, the field of cell therapies is expanding, and there is so much promise,” she says. “The promise of AI, big data, all the engineering tools that we have available, the promise of CRISPR — all of that is going to bring what we've learned from biology, from basic science, together to help us make the cell therapies that are going to be safe and and also very effective for our patients.”

A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

7 Hills Pharma, an innovative immunotherapy company, was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas. Photo via Getty Images

Houston immunotherapy company to use $13.5M grant to further develop cancer treatments

future of pharma

Between Bangalore and Chennai in the Indian state of Andhra Pradesh, you’ll find the town of Tirupati. It’s home to seven peaks that host a Hindu temple complex devoted to a form of Vishnu, Venkateshvara. It is also the region from which Upendra Marathi originally hails. It’s where his father, and many other family members, attended medical school.

“My father’s first job was to take care of the pilgrims,” recalls Marathi.

It's only natural that his groundbreaking Houston company would be named 7 Hills Pharma.

“That sort of selflessness and giving back, I wanted to embody it in the name of the company,” Marathi says.

Now, 7 Hills Pharma is announcing that last month, it was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). That’s on top of more than $13 million in NIH grants, making the company the second largest recipient of SBIR/STTR grants in Texas.

Launched in 2016, 7 Hills Pharma is working to develop drugs that can overcome the all-too-common problem of immunotherapy resistance. Thanks to the Nobel Prize-winning work of Jim Allison in the realm of immuno-oncology, the field was “very hot” at the time, says Marathi, particularly in Houston.

So what has 7 Hills developed? Oral small molecules that activate integrins — the receptors that allow cells to bind to one another — allowing for the cell-to-cell interactions that create a successful immune response to immune checkpoint inhibitors such as Yervoy. In other words, they have created capsules that increase the effectiveness of drugs that allow the body’s own immune response to fight cancers.

But that’s not all. Tests have shown that the same discovery, called alintegimod, can also augment the effectiveness of vaccines. The pill, which co-founder and co-inventor Peter Vanderslice calls “a beautiful way to amplify the vaccines,” can potentially be applied to anything from influenza to coronavirus.

Their greatest challenge, says Vanderslice, is the very fact that the technology is so novel.

“Most large pharmas are very risk averse,” he explains. “They only want to do ‘me-too’ kinds of drugs.”

7 Hills Pharma is the third company Marathi, both a PhD and an MBA, has helped to found based on technology he co-invented. Vanderslice is director of the molecular cardiology research laboratories at The Texas Heart Institute.

“It’s very much a homegrown company,” Marathi says.

And a small one, at least for now. Working out of JLabs@TMC, the full-time team is currently just Marathi and Siddhartha De, the senior director of development. Marathi convinced De to transplant himself and his family from India for the purpose of assisting 7 Hills with preparing its drugs for clinical readiness.

The CPRIT funds will allow 7 Hills Pharma to hire several long-time team members full-time and with benefits.

“The bringing of talent and bringing of technology to TMC and what was born at Texas Heart Institute is rather remarkable,” says Rob Bent, the company’s director of operations.

The next step for 7 Hills Pharma is a Phase Ib/IIa clinical trial in patients with treatment-resistant solid tumors. And the team just finalized the deck that will help raise another $10 million to $250 million in the company’s series A. And hopefully sooner rather than later, a new set of medical pilgrims will be thanking 7 Hill Pharma for its care.

A UH professor is fighting cancer with a newly created virus that targets the bad cells and leaves the good ones alone. Photo via Getty Images

University of Houston researchers snag $1.8M to develop cancer-fighting virus

immunotherapy innovation

Viruses attack human cells, and that's usually a bad thing — some Houston researchers have received fresh funding to develop and use the evil powers of viruses for good.

The developing cancer treatment is called oncolytic virotherapy and has risen in popularity among immunotherapy research. The viruses can kill cancer cells while being ineffective to surrounding cells and tissue. Basically, the virus targets the bad guys by "activating an antitumor immune response made of immune cells such as natural killer (NK) cells," according to a news release from the University of Houston.

However exciting this rising OV treatment seems, the early stage development is far from perfect. Shaun Zhang, director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston, is hoping his work will help improve OV treatment and make it more effective.

“We have developed a novel strategy that not only can prevent NK cells from clearing the administered oncolytic virus, but also goes one step further by guiding them to attack tumor cells. We took an entirely different approach to create this oncolytic virotherapy by deleting a region of the gene which has been shown to activate the signaling pathway that enables the virus to replicate in normal cells,” Zhang says in the release.

Zhang, who is also a M.D. Anderson professor in the Department of Biology & Biochemistry, has received a $1.8 million grant from the National Institutes of Health to continue his work.

Zhang and his team are specifically creating a new OV — called FusOn-H2 and based on the Herpes simplex 2 virus.

“Our recent studies showed that arming FusOn-H2 with a chimeric NK engager (C-NK-E) that can engage the infiltrated natural killer cells with tumor cells could significantly enhance the effectiveness of this virotherapy,” he says. “Most importantly, we observed that tumor destruction by the joint effect of the direct oncolysis and the engaged NK cells led to a measurable elicitation of neoantigen-specific antitumor immunity.”

Shaun Zhang is the director of the Center for Nuclear Receptors and Cell Signaling at the University of Houston and M.D. Anderson professor in the Department of Biology & Biochemistry. Image via UH.edu

Houston's Nobel Prize winner, Jim Allison, is the star of Breakthrough, which premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App. Photo via SXSW.com

Documentary featuring Houston Nobel Prize winner to air on PBS

to-watch list

Not all heroes wear capes. In fact, our current coronavirus heroes are donning face masks as they save lives. One local health care hero has a different disease as his enemy, and you'll soon be able to stream his story.

Dr. James "Jim" Allison won the 2018 Nobel Prize in Physiology or Medicine for his work in battling cancer by treating the immune system — rather than the tumor. Allison, who is the chair of Immunology and executive director of the Immunotherapy Platform at MD Anderson Cancer Center, has quietly and often, singularly, waged war with cancer utilizing this unique approach.

The soft-spoken trailblazer is the subject of an award-winning documentary, Jim Allison: Breakthrough, which will air on PBS and its streaming channels on Monday, April 27 at 9 pm (check local listings for channel information). Lauded as "the most cheering film of the year" by the Washington Post, the film follows Allison's personal journey to defeat cancer, inspired and driven by the disease killed his mother.

Breakthrough is narrated by Woody Harrelson and features music by Willie Nelson, adding a distinct hint of Texana. (The film was a star at 2019's South by Southwest film festival.) The documentary charts Alice, Texas native as he enrolls at the University of Texas, Austin and ultimately, cultivates an interest in T cells and the immune system — and begins to frequent Austin's legendary music scene. Fascinated by the immune system's power to protect the body from disease, Allison's research soon focuses on how it can be used to treat cancer.

Viewers will find Allison charming, humble, and entertaining: the venerable doctor is also an accomplished blues harmonica player. Director Bill Haney weaves Allison's personal story with the medical case of Sharon Belvin, a patient diagnosed with melanoma in 2004 who soon enrolled in Allison's clinical trials. Belvin has since been entirely cancer-free, according to press materials.

"We are facing a global health challenge that knows no boundaries or race or religion, and we are all relying on gifted and passionate scientists and healthcare workers to contain and ultimately beat this thing," said Haney, in a statement. "Jim Allison and the unrelenting scientists like him are my heroes – and I'll bet they become yours!"

Jim Allison: Breakthrough premieres on Independent Lens at 9 pm Monday, April 27, on PBS, PBS.org, and the PBS Video App.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Woodlands startup Mavria raises $130M to mass-produce AI data centers

seed funding

The Woodlands-based Mavria, which mass-produces factory-built modular AI data centers, just emerged from stealth mode with $130 million in funding at a $1 billion valuation.

Mavria raised the money in pre-seed and seed rounds led by Paradigm, an investment firm that concentrates on early-stage startups developing “pioneer” technology. Participants in the funding rounds include AMP PBC, Critical Frontier, Dream Ventures and Liquid 2 Ventures, co-founded by former NFL quarterback Joe Montana.

The company’s inaugural product, Terrain, is a prefabricated data center designed for AI labs, cloud computing providers and data center developers. Mavria says its platform avoids ground-up construction, delivering infrastructure more quickly and at a lower cost.

Mavria tells the Wall Street Journal that the first Terrain unit is being built at a Houston-area factory. The 5-megawatt Terrain system features power distribution, direct liquid cooling, controls and server racks.

“America sets the pace at the intelligence frontier. But the race is moving from the lab into the physical world,” Adam Blake, co-founder and CEO of Mavria, wrote in a blog post.

“Intelligence needs data centers. Data centers need power. Power needs factories, equipment, supply chains, and skilled workers, but much of that infrastructure is still built one custom project at a time, on timelines measured in years.”

Blake and Mavria’s two other co-founders, Nick Poradek and Seth Cohen, most recently worked at the U.S. Department of Energy. There, they focused on reforming the nuclear power sector.

From start to finish, it can take roughly three to six years to build a data center at an estimated cost of $10 million to $37 million per megawatt. Based on those figures, a 100-megawatt data center might cost as much as $3.7 billion.

Here are brief bios of Blake, Poradek and Cohen, who co-founded Mavria in May.

Adam Blake

Blake most recently was a senior advisor to U.S. Energy Secretary Chris Wright. He is co-founder and former CEO of Zego, a provider of energy management technology for property managers. Zego spun out from Brightergy, a commercial solar company. Blake is founder and former CEO of Brightergy.

Nick Poradek

Poradek, chief operating officer at Mavria, was also an advisor to the U.S. energy secretary. He is founder and former CEO of Spring-based Edera Energy, co-founder of The Woodlands-based craft-ice brand Clarity Ice, and founder and former CEO of The Woodlands-based Edera Capital. Poradek sold Edera Energy, a manufacturer of oilfield equipment, to Liberty Energy, a fracking company. Wright is Liberty’s founder and former chairman and CEO.

Seth Cohen

Cohen, chief strategy officer and chief legal officer at Mavria, was head of nuclear law and policy at the Department of Energy. He is also a former NASA advisor and a former attorney at Kirkland & Ellis.

“We believe in rapidly deploying infrastructure as a product, rather than custom-building every project,” Blake said. “We’re bringing together engineering, manufacturing, supply chains and capital so that every project makes us better at delivering the next.”

Meet the 40+ finalists for the 2026 Houston Innovation Awards

The Top Startups

Editor's note: We are just days away from unveiling the winners of the 2026 Houston Innovation Awards. Before the big reveal, we've compiled all of the coverage of this year's finalists. Get to know the 40+ finalists for nine awards categories below, then stay tuned to InnovationMap.com, where we'll announce the winners on Wednesday, November 18.

Minority-founded Business Finalists 

Our Minority-founded Businesses category honors innovative Houston startups founded or co-founded by BIPOC or LGBTQ+ representation. Five minority-founded businesses have been named finalists for the 2026 award. The finalists range from an AI edtech startup to a company operating in the floating offshore energy infrastructure sector.

They are: AI Made Fun, Deep Anchor Solutions, HEXASpec, Prana Surgical, and Torres Orbital Mining Inc. Read more.

Female-founded Business Finalists

Houston is home to many standout female founders, making inroads and breakthroughs in every industry. Our Female-founded Business category honors women-led startups that are shaping Houston innovation. Five female-founded businesses have been named finalists for the 2026 award. The finalists range from an AI startup for C-Suite execs to a company developing semi-autonomous crawler robots for corrosion detection.

They are: Adair, ARIX Technologies, Bairitone Health, FlowCellutions, and ParaDocs Health. Read more.

Health Tech Business Finalists

Houston has been driving medical innovation for decades and the local healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for. The Health Tech Business category in our 2026 Houston Innovation Awards honors innovative startups within the health and medical technology sectors. Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

They are: Bairitone Health, InformAI Inc., Prana Surgical, and Skybound MedTech. Read more.

Deep Tech Business Finalists

Houston has long been at the forefront of innovation, from NASA’s Johnson Space Center to its startup ecosystem using technology to disrupt industries. Our Deep Tech Business category honors innovative startups providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics and space sectors. Five deep tech companies have been named finalists for the 2026 award.

They are: Casimir, FocisAI, Machine Saver Inc., Square Robot, and Venus Aerospace. Read more.

Energy Transition Business Finalists

Houston is home to a growing number of startups reshaping what it means to be called the "Energy Capital of the World." Our Energy Transition Business category honors those innovative startups that are providing solutions within renewables, climatetech, clean energy, alternative materials, circular economy, and more. Five clean energy startups have been named finalists for the 2026 award. The finalists range from a lower-emission steel producer to a diagnostics platform developer working to support batteries used in data centers.

They are: Capwell Services, FlowCellutions, Hertha Metals, Mars Materials, and Solidec. Read more.

Scaleup of the Year Finalists

From IPOs to groundbreakings, some of Houston's most innovative companies reached major milestones this year. Our Scaleup of the Year category honors innovative later-stage startups that have recently reached a significant milestone in company growth. Three scaleups have been named finalists for the 2026 award.

They are: Erock, Hertha Metals, and Venus Aerospace. Read more.

Incubator/Accelerator of the Year Finalists

It takes a village to launch a business. That's where Houston's network of incubators and accelerators can step in, providing the resources, mentorship and community needed to push a fledgling company forward. Our Incubator/Accelerator of the Year category honors local organizations that are championing and fueling the growth of Houston startups. Three incubators and accelerators have been named finalists for the 2026 award. They support startups ranging from hard-tech companies to food and youth concepts.

They are: Activate, Impact Hub Houston, and MarMo Innovation. Read more.

Startup of the Year Finalists

Seven exceptional finalists are in the running for the title of Startup of the Year, which is our people's choice award in the annual Houston Innovation Awards. From innovative platforms benefiting the education, commerce, health, investment and IT sectors to next-gen memory technology and improvements for robotic supply chains, these startups are making an impact in Houston and beyond.

The finalists are: Fluxworks, IronLattice, Lumino, Progress Report, Rosarium Health, TokenRoster, and Thread. Read more.

Mentor of the Year Finalists

Houston’s thriving startup ecosystem is supported by a network of experienced leaders who work behind the scenes, investing their time and knowledge to help the next generation of entrepreneurs succeed. Our Mentor of the Year category honors those who dedicate their time and expertise to guide and support budding entrepreneurs. Six individuals have been named finalists for the 2026 award. They support promising startups in the medical tech, digital health, clean energy, hardware sectors and more.

They are: Al Danto, Rice University; Eric Rubenstein, New Climate Ventures; Jeremy Pitts, Activate; Joe Alapat, Liongard; Kyle Judah, Rice University's Liu Idea Lab for Innovation & Entrepreneurship; Rachel Bickham, Bickham Services Unlimited LLC. Read more.